Treatment Of Patients With Metastatic Melanoma Using Nonmyeloablative But Lymphocyte Depleting Regimen Followed By The Administration Of In Vitro Sensitized Lymphocytes Reactive With ESO-1 Antigen

Fecha de inicio: 1 de enero de 2004

DISEASE CHARACTERISTICS: * Diagnosis of metastatic melanoma that is refractory to standard therapy (including high-dose interleukin-2) * Measurable disease * HLA-A\*0201 positive * Epstein-Barr virus positive * ESO-1-expressing disease by reverse transcription polymerase chain reaction amplified tissue OR presence of ESO-1 serum antibody PATIENT CHARACTERISTICS: Age * 16 and over Performance status * ECOG 0-1 Life expectancy * More than 3 months Hematopoietic * Absolute neutrophil count \> 1,000/mm\^3 * Platelet count \> 100,000/mm\^3 * Hemoglobin \> 8.0 g/dL Hepatic * Hepatitis B surface antigen negative * Hepatitis C antibody negative * AST and ALT \< 3 times upper limit of normal * Bilirubin ≤ 2.0 mg/dL (\< 3.0 mg/dL for patients with Gilbert's syndrome) * No coagulation disorders Renal * Creatinine ≤ 2.0 mg/dL Cardiovascular * No prior myocardial infarction * No major cardiovascular illness by stress thallium or comparable test * No cardiac arrhythmias * LVEF ≥ 45% * Normal cardiac stress test required for the following conditions: * Prior EKG abnormalities * Symptoms of cardiac ischemia * Arrhythmias * Age 50 and over Pulmonary * FEV\_1 \> 60% of predicted (for patients with a prolonged history of cigarette smoking or symptoms of respiratory dysfunction) * No obstructive or restrictive pulmonary disease * No other major respiratory illness Immunologic * HIV negative * No active systemic infection * No opportunistic infection * No major immune system illness * No form of primary or secondary immunodeficiency * No known hypersensitivity to study agents Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for at least 4 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy * See Disease Characteristics * Prior ESO-1-based vaccination allowed Chemotherapy * At least 6 weeks since prior nitrosoureas and recovered Endocrine therapy * No concurrent systemic steroid therapy Radiotherapy * Recovered from prior radiotherapy Surgery * Not specified Other * At least 4 weeks since prior systemic therapy